0.8134
6.40%
+0.0489
After Hours:
.82
0.0066
+0.81%
Gritstone Bio Inc stock is currently priced at $0.8134, with a 24-hour trading volume of 1.10M.
It has seen a +6.40% increased in the last 24 hours and a -68.59% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.7758 pivot point. If it approaches the $0.8328 resistance level, significant changes may occur.
Previous Close:
$0.7645
Open:
$0.7583
24h Volume:
1.10M
Market Cap:
$86.54M
Revenue:
$1.33M
Net Income/Loss:
$-138.49M
P/E Ratio:
-0.6456
EPS:
-1.26
Net Cash Flow:
$-126.22M
1W Performance:
+10.43%
1M Performance:
-68.59%
6M Performance:
-58.29%
1Y Performance:
-65.82%
Gritstone Bio Inc Stock (GRTS) Company Profile
Name
Gritstone Bio Inc
Sector
Industry
Phone
510-871-6100
Address
5858 Horton Street, Suite 210, Emeryville, CA
Gritstone Bio Inc Stock (GRTS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-31-23 | Initiated | Evercore ISI | Outperform |
Mar-28-23 | Initiated | B. Riley Securities | Buy |
Oct-31-22 | Initiated | Piper Sandler | Overweight |
Aug-22-22 | Downgrade | Goldman | Neutral → Sell |
Dec-15-21 | Resumed | Goldman | Neutral |
Oct-15-21 | Resumed | BTIG Research | Buy |
Jan-20-21 | Downgrade | Robert W. Baird | Outperform → Underperform |
Jul-26-19 | Initiated | Robert W. Baird | Outperform |
Mar-15-19 | Initiated | Raymond James | Outperform |
Mar-07-19 | Initiated | H.C. Wainwright | Buy |
Oct-23-18 | Initiated | BTIG Research | Buy |
Oct-23-18 | Initiated | Goldman | Neutral |
View All
Gritstone Bio Inc Stock (GRTS) Latest News
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
Zacks Investment Research
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Seeking Alpha
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
Zacks Investment Research
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
Benzinga
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Crude Oil Surges Over 1%; US Factory Orders Increase In February
Benzinga
Gritstone Bio Inc Stock (GRTS) Financials Data
Gritstone Bio Inc (GRTS) Revenue 2024
GRTS reported a revenue (TTM) of $1.33 million for the quarter ending December 31, 2023, a -85.63% decline year-over-year.
Gritstone Bio Inc (GRTS) Net Income 2024
GRTS net income (TTM) was -$138.49 million for the quarter ending December 31, 2023, a -15.71% decrease year-over-year.
Gritstone Bio Inc (GRTS) Cash Flow 2024
GRTS recorded a free cash flow (TTM) of -$126.22 million for the quarter ending December 31, 2023, a -3.61% decrease year-over-year.
Gritstone Bio Inc (GRTS) Earnings per Share 2024
GRTS earnings per share (TTM) was -$1.20 for the quarter ending December 31, 2023, a +9.77% growth year-over-year.
About Gritstone Bio Inc
Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.
Cap:
|
Volume (24h):